Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $20.00 USD
Change Today -0.28 / -1.38%
Volume 549.0K
OMER On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 8:10 PM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

omeros corp (OMER) Snapshot

Open
$20.28
Previous Close
$20.28
Day High
$20.49
Day Low
$19.86
52 Week High
03/5/15 - $27.64
52 Week Low
06/2/14 - $11.08
Market Cap
756.6M
Average Volume 10 Days
457.1K
EPS TTM
$-2.19
Shares Outstanding
37.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OMEROS CORP (OMER)

omeros corp (OMER) Related Bloomberg News

View More Bloomberg News

omeros corp (OMER) Related Businessweek News

No Related Businessweek News Found

omeros corp (OMER) Details

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. It markets Omidria for use during cataract surgery or intraocular lens, or replacement surgery. The company’s clinical products include OMS721 that is in Phase II clinical trials for the treatment of various complement-mediated disorders, including complement-mediated thrombotic microangiopathies; OMS824, which is in Phase II clinical trials for the treatment of CNS disorders comprising schizophrenia and Huntington's disease; and OMS103 that has completed Phase III clinical trials for use during arthroscopic procedures, such as partial meniscectomy surgery. Its clinical programs also comprise OMS405, which is in Phase II clinical trials for the treatment and prevention of addiction to substances of abuse; and OMS201 that has completed Phase I/II clinical trials for use during urological procedures, such as ureterscopy for removal of ureteral or renal stones. The company’s preclinical programs also comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders, such as Parkinson's disease; OMS616 for the control of blood loss during surgery, or resulting from trauma or other hyperfibrinolytic conditions; and OMS906 for the treatment of paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. In addition, its preclinical products consist of GPR17 for the treatment of demyelinating disorders; G protein-coupled receptor platform for multiple disorders across therapeutic area; and antibody platform for the discovery of monoclonal antibodies. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.

103 Employees
Last Reported Date: 03/16/15
Founded in 1994

omeros corp (OMER) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $684.1K
Principal Financial Officer, Chief Accounting...
Total Annual Compensation: $285.0K
Vice President of Patent, General Counsel and...
Total Annual Compensation: $352.6K
Compensation as of Fiscal Year 2014.

omeros corp (OMER) Key Developments

Omeros Corporation Receives Positive Opinion for Omidria from European Medicines Agency's Committee for Medicinal Products for Human Use

Omeros Corporation announced that the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Omidria® (phenylephrine and ketorolac injection) 1%/0.3%. Omidria is used during cataract surgery and other intraocular lens (IOL) replacement procedures to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction), and reduce postoperative eye pain. Cataract surgery and IOL replacement are among the most common surgical procedures worldwide, with approximately 3.9 million of them expected to be performed in Western Europe alone in 2015. The positive opinion adopted for Omidria by CHMP was supported unanimously by committee members and represents an intermediate step toward patient access to Omidria in Europe. No post-marketing follow-up studies or measures were recommended by CHMP for Omidria. Next, the CHMP opinion will be reviewed by the European Commission (EC), and the decision by the EC on approval of Omidria will be applicable to all European Union member states plus Iceland, Lichtenstein, and Norway. The EC decision is due approximately two months following CHMP's opinion. Decisions about price and reimbursement for Omidria occur on a country-by-country basis. Omidria was approved by the U.S. Food and Drug Administration in 2014 and last month was made broadly available nationwide for commercial use. The company has received strongly positive feedback from ophthalmic surgeons, the product being used in cataract and IOL replacement surgery both with and without femtosecond laser and in routine as well as complicated cases, including those with intraoperative floppy iris syndrome (IFIS) and pseudoexfoliation, a common cause of glaucoma. Reimbursement for Omidria has been confirmed across each of the U.S. Medicare Administrative Contractor regions.

Omeros Corporation Presents at UBS Global Healthcare Conference, May-19-2015 02:30 PM

Omeros Corporation Presents at UBS Global Healthcare Conference, May-19-2015 02:30 PM. Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Gregory A. Demopulos, Co-Founder, Chairman, Chief Executive Officer and President.

Omeros Corporation Announces Consolidated Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Omeros Corporation announced consolidated unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $388,000 compared with $100,000 for the same period a year ago. Loss from operations was $17,930,000 compared with $15,684,000 for the same period a year ago. Net loss was $18,669,000 or $0.51 per basic and diluted share compared with $16,642,000 or $0.54 per basic and diluted share for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OMER:US $20.00 USD -0.28

OMER Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OMER.
View Industry Companies
 

Industry Analysis

OMER

Industry Average

Valuation OMER Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 894.7x
Price/Book 35.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 803.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OMEROS CORP, please visit www.omeros.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.